Preclinical research finds that glioblastoma stem cells can be targeted by NK cells, but they are able to evade immune attack by releasing TFG-β. Deleting the TFG-β receptor in NK cells renders them resistant to this and restores their anti-tumor activity.
A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology.
Penn Medicine and Children’s Hospital of Philadelphia (CHOP) will host a virtual event on May 6 and 7 that will bring together cell and gene therapy leaders from the two institutions and around the world to discuss the latest achievements in the field, novel strategies, and future developments and applications for chimeric antigen receptor, CAR, T cell therapy and more.
The Wake Forest Institute for Regenerative Medicine is investigating how cats with chronic kidney disease could someday help inform treatment for humans.
SEATTLE — March 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.March is Women’s History month. We’d like to honor Dottie Thomas, known as the “mother of bone marrow transplantation.” She spent years working as a research partner alongside her husband, Nobel Prize-winning Dr.
SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.
Retinal cells derived from a cadaver human eye survived when transplanted into the eyes of primate models, an important advance in the development of cell therapy to treat blindness, according to a study published on January 14 in Stem Cell Reports.
By disabling a function of a set of cells in mice, researchers appear to have halted the process that breaks down bone, a likely boon for osteoporosis treatment
In a new study looking at adoptive cell transfer products bearing a transgenic T-cell receptor (TCR), researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a discordant phenomenon in which a subset of patients displayed profoundly decreased expression of the transgenic TCR over time, despite the transgenic TCR being present at the DNA level.
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
Ziopharm and MD Anderson have announced a new research and development agreement to develop novel T-cell therapies using engineered T-cell receptors for solid tumors.
Dr. Christopher E. Rudd has discovered a new cell therapy approach that boosts the immune response of T lymphocytes to malignant tumours.